Abstract: A method for treating a bacterial, viral, fungal, or vector-induced disease state. A therapeutically effective dose of a metal substance is delivered to the body of a potentially infected organism using a delivery methodology selected from the group consisting of syringes, auto-injectors, pricking devices, buccal embedding, transdermal patches, needle transdermal patches, aerosol inhalers, ingestible dissolvable capsules, encapsulated boluses, needle encapsulated boluses, and electrode catheterization methodologies. The metal substance is selected from the group consisting of silver, gold, copper, zinc, selenium, platinum, and their ions, alloys, salts, and combinations thereof. Preferably, an electrical current is introduced substantially in the course of utilizing the delivery methodology. The electrical current is preferably substantially varied over time, and is still more preferably a reversing electrical current.

Abstract: The present invention relates to compositions and methods for alleviating the painful symptoms due to neuropathy. Specifically, the method involves administering to a patient a composition comprising a nitric oxide donor that may be applied topically on the legs or arms to alleviate the negative effects due to neuropathy.

Abstract: Provided, among other things, is a delivery module for a non-greasy, water-based urea composition comprising: an aerosol delivery device; within the aerosol delivery device, the urea composition comprising 20% or more urea by weight, non-greasy lipophilic component(s), and a frothing agent, the urea composition having a viscosity low enough to support aerosol delivery, and the urea composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery device, a propellant.

Abstract: Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues).

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: There is described a colored or colorable topical composition, comprising: a) a foamable base composition comprising, 1) a flowable carrier composition; 2) a color agent; wherein the color agent is effective to impart, increase, decrease or otherwise affect color of a foam produced from the foamable composition and wherein the color agent is one or more agents selected from the group consisting of a colored active agent, a colored indicator, a colored excipient, a pigment, a dye, a colorant and a coloring agent; b) a propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the base composition has a first color; and wherein the foam comprising the colored or colorable topical composition has a second color upon dispensing from an aerosol container, and wherein the first color and the second color are visually different. There is also described a method of changing color, a method of administration, a use as a diagnostic and a kit.

Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.

Abstract: The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof. The present invention further teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent, and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof.

Abstract: The invention relates to an effervescent formulation containing florfenicol or an antibiotic of related structure. When introduced into water, the effervescent formulation is dissolved with minimal or no agitation and provides a solution or a homogeneous dispersion of florfenicol. The formulations are typically in the form of free flowing powders, granules or tablets. The effervescent formulations are useful for the treatment of bacterial infections and allow for the rapid dispersion and dissolution of florfenicol in the drinking water systems of an animal in need of such treatment.

Abstract: The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation.

Abstract: This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.

Abstract: Aerosol solution formulations for use in an aerosol inhaler which comprise 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]-ethyl]-2(1H)-quinolinone or a salt thereof, in particular the hydrochloride salt (TA 2005), as an active ingredient, a propellant containing a hydrofluoroalkane, and a cosolvent, stabilized by addition of a specific small amount of a high concentrated phosphoric acid exhibit improved shelf life. The formulation may be optionally contained in a can having part or all of its internal metallic surfaces lined with an inert organic coating.

Abstract: The present invention provides a hydrostatic delivery system comprising a hydrostatic couple and an agent of interest. The hydrostatic couple comprises, at least one hydrodynamic fluid-imbibing polymer, and at least one hydrostatic pressure modulating agent. This delivery system has the ability to control the release of one or more agent of interest within a fluid environment following zero-order kinetics.

Abstract: The present invention is directed to a method for treating allergic rhinitis without causing an adverse effect of bitter taste. The method comprises administering to a patient an aqueous pharmaceutical formulation comprising 0.1-0.15% (w/v) of epinastine or an acid addition salt thereof, 0.05-0.5% (w/v) of hydroxypropylmethylcellulose to maintain the viscosity between 1.5-10 centipoise, 1-2% (w/v) of propylene glycol, and a buffer to maintain the pH between 5-8, said aqueous epinastine formulation has a tonicity between 200-400 mOsm/kG; the formulation does not contain a sweetening agent. The present invention provides a method for effectively treating allergic rhinitis by delivering a small volume of the epinastine formulation to the nose of a patient using a small volume metered-dose nasal spray pump. The present method does not cause an adverse effect of bitter taste without including sweetening agents in the formulation.

Abstract: Gastrointestinal conditions, such as gastroesophageal reflux disease, heartburn, acid indigestion, constipation, irritable bowel syndrome, stomach and intestinal ulcers, gastrointestinal tract inflammation, thrush, diverticulitis, ulcerative colitis, Crohn's disease, diarrhea and cancers of the esophagus, pancreas, stomach, intestines and colon, may be treated or prevented by administration of compositions containing a therapeutically effective amount of a fatty acid and a therapeutically effective amount of mucilaginous fiber. Fatty acids suitable for use in the compositions include omega-3 fatty acids, omega-6 fatty acids and/or omega-9 fatty acids.

Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.

Abstract: Disclosed is a wound healing composition comprising a mixture of substances that are obtained from diptera larvae, are heat-resistant at 100° C., and have molecular weights ranging from 500 to 10,000 Dalton. Also, disclosed are the use of said composition as well as a method for the production thereof.

Abstract: Film-forming and cosmetic compositions containing a combination of certain polyhedral oligomeric silsesquioxanes (POSS) and non-POSS silicone resins are described, the combination providing improved wear and/or pliability properties over previous silicone resin containing compositions. Typically, the advantageous combinations will be formulated in a cosmetic composition that contains at least one solvent, and, preferably, a colorant, such as a pigment. Other cosmetic ingredients known to those of skill in the art can also be combined therewith, depending on the desired product, such as a foundation, mascara, lip coating (lip stick, lip gloss, lip pencil and the like), nail coating and the like. Methods of making cosmetic compositions including combinations of a POSS and non-POSS silicone resin providing the advantageous properties are also described.

Abstract: The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal.

Abstract: A therapeutic agent and methodology for treatment of tonsillitis and tonsil, throat and mouth infection is provided as a combination of Lactic Acid and a delivery vehicle, such as an ingestible liquid. The agent is ingested by an individual with a spacing between applications thereof, such that recurrence of tonsil infection is suppressed.

Abstract: Among the various aspects of the present invention is an improved process for the preparation of polyamino acids generally, and more specifically, polyglutamic acid and polyaspartic acid. Another aspect is a process for the large scale (i.e. >1 kg) preparation of polyamino acids; particularly polyglutamic and polyaspartic acid.

Abstract: Certain surfactants suitable for use alone to dissolve a water-insoluble component in compositions is described for providing VOC-free compressed gas aerosol compositions. The compositions include water-insoluble component(s), a surfactant and water. The water-insoluble component(s) can be active agent(s), such as fragrance(s) and/or an insecticide(s). The surfactant is present as a single surfactant which, in the absence of a solvent, dissolves or disperses the water-insoluble component(s) and provides a homogenous blend in water which provides a stable compressed gas emulsion.

Abstract: Particles having a tap density less than about 0.4 g/cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery.

Abstract: A method of treating an instrument after contamination of a surface thereof includes the steps of covering the surface with a foam and maintaining the foam on the surface to keep the surface moist prior to cleaning the instrument to prevent foreign matter thereon from becoming dried on and more difficult to remove during cleaning. The foam includes hydrogen peroxide, dissolves blood and provides antimicrobial effect.

Abstract: A non-lethal temporarily incapacitating formulation having a new solvent system that has reduced blow back longer hang time when used as an aerosol spray. The solvent and formulation are non-toxic, non-hazardous, non-flammable, highly stable, environmentally safe and able to withstand extreme operating temperatures. The solvent system is a mixture of propylene glycerol dicaprylate/caprate and glycerol tris (2-ethylhexanoate) and is suitable for use for a wide range of automotive, household and industrial applications.

Abstract: A pharmaceutical composition to be externally applied as a topical preparation for treating several diseases, the composition comprising dimethylsulfoxide (DMSO) and ozone. A method for obtaining the composition by ozonizing DMSO and a method for treating diseases by applying the composition are also provided.

Abstract: Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to treat erectile dysfunction or a combination of the testosterone and the other drug where at least one is delivered by aersolization. The formulation is preferably aerosolized and inhaled into a patient's lungs where particles of testosterone and/or the fast-acting erectile dysfunction drug deposits on lung tissue and then enter the patient's circulatory system.

Abstract: The invention is a preparation comprising an oil-in-water emulsion containing soap, the emulsion further comprising: (a) 4-12% by weight of at least one fatty acid with 12 to 18 carbon atoms, (b) 3-8% by weight of at least one trialkanolamine, (c) 1-8% by weight of at least one nonionic emulsifier, (d) 0-3% by weight of a fatty alcohol or fatty alcohol mixture, (e) 0.1-6% by weight of one or more emollients, (f) 1-10% by weight propellant with a vapor pressure of 76 to 420 kPa at 20° C., (g) 0-1% by weight of at least one cellulose derivative, and (h) 0.1-4% by weight of at lest one glycerol polyglycol ether isostearate, wherein the oil-in-water emulsion is free from fatty acid diethanolamides, and wherein the preparation is suitable for filling in an aerosol container. The invention also includes a pressurized gas container containing the preparation.

Abstract: Novel compositions for the treatment of IRDS and ARDS are indicated which contain a compound of formula (I), in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt of this compound and lung surfactant

Abstract: A one-pack aqueous aerosol composition being highly secure against fire and enabling efficient adhesion of an active ingredient. This aerosol composition is a homogeneous one which comprise 10 to 60 wt % of a liquid concentrate consisting of 30 to 90 wt % of an oil such as kerosene, 5 to 50 wt % of a polyhydric alcohol such as diethylene glycol, 1 to 40 wt % of water, and 0.1 to 20 wt % of an active ingredient such as insecticide and not exhibiting any flash point at a pressure of 1 atm and 90 to 40 wt % of a propellant consisting of diethyl ether.

Abstract: There is provided according to the invention a pharmaceutical aerosol formulation which comprises: (i) fluticasone propionate and (ii) a hydrofluoroalkane (HFA) propellant, characterised in that the fluticasone propionate is completely dissolved in the formulation. The invention also provided canisters containing the formulation and uses thereof.

Abstract: A method and device for metered delivery of an insecticidal liquid into a room for the purpose of repelling or killing flying insects, wherein the liquid is ejected in small quantities from a bubble-jet type liquid emanator device at an ambient temperature. The ejected droplets may also be charged to (?1×10?4 C/Kg) by passing the droplets through a static field which will cause the droplets to be attracted to the positive charge which exists across the insects cuticle. Other applications include dispensation of fragrances and air fresheners into a room.

Abstract: There is disclosed an antimicrobial composition that may be used in the treatment of diseases and conditions associated with farm animals and livestock. The composition may also be utilized as an inhibitor of microbial growth on crops, plants or foodstuffs, such as grains and the like. The composition comprises an antimicrobially effective amount of clove bud oil, eucalyptus oil, lavender oil, tea tree and orange oil but may be diluted with water prior to application.

Abstract: The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising an acid or amine end-group and at least one and no more than two amide and/or ester functional groups, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient containing an acid or amine end-group and at least one and no more than two amide and/or ester functional groups.

Abstract: The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.

Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.

Abstract: Probucol derivatives and pharmaceutical compositions containing the same to be employed in treatment or prophylaxis of diseases.

Abstract: An effervescent solid composition of matter is provided, which comprises, as an active component, a substance selected from chitosan, its derivatives and salts thereof and a second component capable of releasing CO2 in an acidic environment. Also, methods for treatment of a mammal suffering from a dermal wound, or for prophylactic or wound-healing treatment of lactating animals prone to develop or suffering from mastitis, are provided. The methods comprise the steps of: a) admixing said effervescent solid composition of matter with an aqueous liquid to form a solution or suspension thereof; b) contacting said animals with said solution or suspension to provide such treatment.

Abstract: Aqueous compositions as well as processes and devices are disclosed for spray application on an air scenting device to provide long lasting freshening or scenting of air flowing through the device with minimal blockage of air flow through the device. The compositions contain a polymeric emulsion, a surfactant and a fragrance material and also may optionally include a rheological agent and/or an anti-microbial agent.

Abstract: Provided is a compressed anti-solvent technique for manufacture of drug-containing powders for pulmonary delivery. The drug is processed in a cosolvent system including two or more mutually soluble organic solvents. Also provided are powders manufacturable by the manufacture method, including powders of substantially pure drug and powders including a biocompatible polymer for pulmonary sustained drug release applications. Also provided are packaged products including drug-containing powder in a container that is receivable by and operable with a dry powder inhaler to produce an aerosol including dispersed drug-containing particles when the inhaler is actuated.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: Disclosed is a spray pack for use in forming a uniform, stable spray coating, comprising a spray container device and, packed therein, a spraying composition comprising a liquid dispersion medium and, dispersed therein, particulate cellulose having an average degree of polymerization (DP) of not more than 300 and an average particle diameter of not more than 10 ?m, wherein the composition has a cellulose content of from 0.1 to 5.0% by weight, and wherein the composition exhibits a maximum viscosity value (?max) of 1×103 mPa·s or more in the viscosity-shear stress curve obtained, with respect to the composition, using a cone-plate type rotating viscometer in a shear rate region of from 1×10?3 s?1 to 1×102 s?1 and at 25° C. A method for forming a uniform, stable spray coating by using the above-mentioned spray pack is also disclosed.

Abstract: Method and system of producing microparticles loaded with biologically active drugs, including proteins such as ICAM-1, for controlled release of the drugs in a nasal passageway. The method includes introducing a drug/polymer feed solution and an emulsifier into a first mixing chamber to create an emulsion, then mixing a cross-linking agent together with the emulsion under controlled conditions to create microparticles loaded with the drug. The system includes a first mixing chamber, in which the emulsion is created, having a first port for introducing the drug/polymer solution, and a second port angled substantially perpendicular to the first port for introducing the emulsifier. A second mixing chamber adjacent to the first mixing chamber receives the emulsion and either contains a cross-linking agent or receives a stream of a cross-linking agent to solidify the microparticles.

Abstract: A foamable pharmaceutical composition comprising a corticosteroid, a quick-break foaming agent, a propellant and a buffering agent, sufficient to buffer the composition to within the range of pH 3.0 to 6.0 is disclosed. The quick-break foaming agent typically comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent. Due to the nature of the compositions of the invention, they are especially well-suited for use in the treatment of various skin diseases, and in particular, in the treatment of scalp psoriasis.

Abstract: This invention relates to a medicinal aerosol suspension formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug or a combination of at least two particulate drugs, a propellant and a stabilizing agent comprising a water addition.

Abstract: There is provided a topical composition that comprises (a) a substantially anhydrous insect repellent selected from the group consisting of ethyl 3-(N-butylacetylamino) propionate or a derivative thereof, p-menthane-3,8-diol, hydroxyethyl isobutyl piperidine carboxylate (1-piperidine carboxylic acid), and mixtures thereof, and (b) a non-volatile solvent. A second embodiment of the present composition includes the same insect repellent, and a volatile solvent, and, optionally, a film former. A third embodiment includes the same insect repellent, a non-volatile solvent, a volatile solvent, and, optionally, a film former.

Abstract: Formulations, methods and devices for producing formulations and methods for nebulizer delivery of formulations of water-insoluble drugs are provided. Also provided are methods for minimizing wastage of drugs administered by nebulizer, and for the achievement of quantitative dosing with diluent from a mass marketed formulations, which because of the mass market is much less costly per dose than formulations manufactured specifically for much lower volume medical use.

Abstract: An aerosol solution composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. The composition is stabilized by using a small amount of mineral acid and a suitable can having part or all of its internal metallic surfaces made of stainless steel, anodized aluminium or lined with an inert organic coating.

Abstract: Pharmaceutical compositions comprising effective amounts of salmeterol (and a physiologically acceptable salt thereof) and fluctuations propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.